Question: What is the impact on overall mortality outcomes (death from any cause) and adverse events of g-csf in the treatment of newborns with neonatal sepsis and neutropenia [absolute neutrophil count (anc)<5,000 mm3] compared to the conventional therapy?11. Silvinato A, Bernardo WB, Floriano I – Neonatal sepsis with neutropenia: granulocytecolony stimulating factor (G-CSF) - REV ASSOC MED BRAS 2020; 66(1):3-10.
Answer: In newborns with sepsis and neutropenia ≤5,000 cells/mm3, the use of g-csf reduces the risk of in-hospital death by 19% (nnt = 5). G-csf has proved to be a safe drug.
REFERENCES
-
1Silvinato A, Bernardo WB, Floriano I – Neonatal sepsis with neutropenia: granulocytecolony stimulating factor (G-CSF) - REV ASSOC MED BRAS 2020; 66(1):3-10.
Publication Dates
-
Publication in this collection
15 June 2020 -
Date of issue
Apr 2020
